Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-3.A2 peptide vaccine
- Development stage
- Phase 2
- Lead developer
- Cliniques universitaires Saint-Luc
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal, Subcutaneous
01
Overview
MAGE-3.A2 peptide vaccine is a cancer immunotherapy peptide vaccine developed and studied by Cliniques Universitaires Saint-Luc (Université Catholique de Louvain) in Belgium. It consists of a synthetic peptide derived from the Melanoma Antigen Gene-3 (MAGE-3) protein (sequence: FLWGPRALV) that binds to the HLA-A2 MHC class I molecule. The vaccine is designed to stimulate an HLA-A2-restricted cytolytic T-lymphocyte (CTL) immune response against MAGE-3-expressing tumor cells. It was evaluated in a Phase 2 clinical trial (NCT00365937) as part of an eight-peptide mixture (including MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NA17.A2, Tyrosinase.A2, and NY-ESO-1.A2) administered with or without adjuvants like Montanide ISA 51 and IMP321 in patients with high-risk cutaneous melanoma. The development of the vaccine was terminated due to regulatory issues with the peptide supplier.
- Other names
- MAGE-3.A2 peptideMAGE3.A2 peptideMAGE 3.A2 peptideMAGE-A3.A2 peptide vaccineMAGE-A-3.A2 peptide vaccineMAGE-A 3.A2 peptide vaccineFLWGPRALV peptide
02
Targets
MAGEA3 (Melanoma-associated antigen 3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on MAGE-3.A2 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-3.A2 peptide vaccine.